Paul G. Richardson | Scholar Profiles and Rankings

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide (journal article) Mo, Clifton C. \| Richardson, Edward \| Calabretta, Eleonora \| Corrado, Francesco \| Kocoglu, Mehmet H. \| Baron, Rebecca M. \| Connors, Jean Marie \| Iacobelli, Massimo \| Wei, Lee-Jen \| Rapoport, Aaron P. \| ... \| Richardson, Paul G. Blood Reviews, volume 66 (2024). 10.1016/j.blre.2024.101218 Cite \| Source
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM). (journal article) Trudel, Suzanne \| Bahlis, Nizar J. \| Popat, Rakesh \| Mateos, Maria-Victoria \| Vangsted, Annette J. \| Ramasamy, Karthik \| Martínez-Lopez, Joaquín \| Quach, Hang \| Orlowski, Robert Z \| Burnett, Joseph \| ... \| Richardson, Paul G. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 7539-7539 (2024). 10.1200/JCO.2024.42.16_suppl.7539 Cite \| Source
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial (journal article) O'Donnell, Elizabeth \| Mo, Clifton \| Yee, Andrew J \| Nadeem, Omar \| Laubach, Jacob \| Rosenblatt, Jacalyn \| Munshi, Nikhil \| Midha, Shonali \| Cirstea, Diana \| Chrysafi, Pavlina \| ... \| Raje, Noopur The Lancet Haematology, volume 11, issue 6, pages e415-e424 (2024). 10.1016/S2352-3026(24)00070-X Cited by (3) \| Cite \| Source
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study (journal article) Nooka, Ajay K. \| Kaufman, Jonathan L. \| Rodriguez, Cesar \| Jakubowiak, Andrzej \| Efebera, Yvonne \| Reeves, Brandi \| Wildes, Tanya M. \| Holstein, Sarah A. \| Anderson, Larry D. \| Badros, Ashraf \| ... \| Richardson, Paul G. British Journal of Haematology, volume 204, issue 6, pages 2227-2232 (2024). 10.1111/bjh.19386 Cite \| Source
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial (journal article) Mateos, Maria‐Victoria \| Engelhardt, Monika \| Leleu, Xavier \| Mesa, Mercedes Gironella \| Cavo, Michele \| Dimopoulos, Meletios \| Bianco, Martina \| Merlo, Giovanni Marino \| Porte, Charles la \| Richardson, Paul G. \| Moreau, Philippe European Journal of Haematology (2024). 10.1111/ejh.14223 Cite \| Source
The Role of Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Multiple Myeloma: Is It Time to Rethink the Paradigm in the Era of Targeted Therapy? (journal article) Richardson, Paul G. Hemato, volume 5, issue 2, pages 144-156 (2024). 10.3390/hemato5020012 Cite \| Source
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study (journal article) Schjesvold, Fredrik H. \| Ludwig, Heinz \| Mateos, Maria‐Victoria \| Larocca, Alessandra \| Abdulhaq, Haifaa \| Norin, Stefan \| Thuresson, Marcus \| Bakker, Nicolaas A. \| Richardson, Paul G. \| Sonneveld, Pieter European Journal of Haematology, volume 112, issue 3, pages 402-411 (2024). 10.1111/ejh.14127 Cite \| Source
Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma (journal article) Hartley-Brown, Monique A. \| Mo, Clifton C. \| Nadeem, Omar \| Midha, Shonali \| Laubach, Jacob P. \| Richardson, Paul G. Cancers, volume 16, issue 6, pages 1166- (2024). 10.3390/cancers16061166 Cite \| Source
Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials (journal article) Laane, Edward \| Salek, Sam \| Oliva, Esther Natalie \| Bennink, Christine \| Clavreul, Solène \| Richardson, Paul G \| Scheid, Christof \| Weisel, Katja \| Ionova, Tatyana Cancers, volume 15, issue 24, pages 5764- (2023). 10.3390/cancers15245764 Cited by (1) \| Cite \| Source
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy (journal article) Mo, Clifton \| Hartley-Brown, Monique \| Midha, Shonali \| Richardson, Paul Cancers, volume 15, issue 24, pages 5709- (2023). 10.3390/cancers15245709 Cited by (1) \| Cite \| Source
The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma (journal article) Rodriguez, Cesar \| Perrot, Aurore \| Richardson, Paul G. \| Facon, Thierry \| Spicka, Ivan \| Oriol, Albert \| Suzuki, Kenshi \| Crusoe, Edvan \| Chari, Ajai \| Armstrong, Nicole \| ... \| Moreau, Philippe Blood, volume 142, issue Supplement 1, pages 1980-1980 (2023). 10.1182/blood-2023-179925 Cite \| Source
A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) (journal article) O'Donnell, Elizabeth K. \| Mo, Clifton C. \| Yee, Andrew J. \| Nadeem, Omar \| Branagan, Andrew R. \| Laubach, Jacob \| Rosenblatt, Jacalyn \| Horick, Nora \| Richardson, Paul G. \| Raje, Noopur \| Cirstea, Diana Blood, volume 142, issue Supplement 1, pages 4671-4671 (2023). 10.1182/blood-2023-181019 Cited by (2) \| Cite \| Source
Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma (journal article) Chow, Tracy T. \| Amatangelo, Michael \| Ma, Peilin \| Bjorklund, Chad C. \| Wollerman, Krista \| Civardi, Tiziana \| Koo, Phillip \| Zhu, Yue \| Maciag, Paulo \| Katz, Jessica \| ... \| Gandhi, Anita K. Blood, volume 142, issue Supplement 1, pages 3318-3318 (2023). 10.1182/blood-2023-178881 Cited by (3) \| Cite \| Source
Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15) (journal article) Efebera, Yvonne \| Suman, Vera Jean \| Dinner, Shira N. \| Rosko, Ashley E \| Mckay, John T \| Barth, Peter \| Hagen, Patrick \| Usmani, Saad Z \| Richardson, Paul G. \| Laubach, Jacob P. Blood, volume 142, issue Supplement 1, pages 3340-3340 (2023). 10.1182/blood-2023-187296 Cite \| Source
Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide (journal article) Cirstea, Diana \| Shome, Rajib \| Connolly, Joseph James \| Duvallet, Emilie \| Joyce, Amanda N. R. \| Moyo, Victor \| Lively, Kathleen \| Basinsky, Gina \| Yee, Andrew J. \| Costa Chase, Cristiana \| ... \| Raje, Noopur S. Blood, volume 142, issue Supplement 1, pages 2017-2017 (2023). 10.1182/blood-2023-189332 Cite \| Source
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial (journal article) Richardson, Paul G. \| Sandhu, Irwindeep \| Hofmeister, Craig C. \| Orlowski, Robert Z. \| White, Darrell \| Belotti, Angelo \| Toftmann Hansen, Charlotte \| Raje, Noopur S. \| Chow, Tracy T. \| Zhou, Zehua \| ... \| Oriol, Albert Blood, volume 142, issue Supplement 1, pages 1013-1013 (2023). 10.1182/blood-2023-174443 Cited by (6) \| Cite \| Source
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma (journal article) Midha, Shonali \| Hartley-Brown, Monique A. \| Mo, Clifton C. \| Hossain, Shahrier \| Nadeem, Omar \| O’Donnell, Elizabeth K. \| Bianchi, Giada \| Sperling, Adam S. \| Laubach, Jacob P. \| Richardson, Paul G. Expert Opinion on Drug Safety, volume 22, issue 11, pages 1049-1071 (2023). 10.1080/14740338.2023.2274420 Cited by (3) \| Cite \| Source
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma (journal article) Bisht, Kamlesh \| Fukao, Taro \| Chiron, Marielle \| Richardson, Paul \| Atanackovic, Djordje \| Chini, Eduardo \| Chng, Wee Joo \| Van De Velde, Helgi \| Malavasi, Fabio Cancer Medicine, volume 12, issue 20, pages 20332-20352 (2023). 10.1002/cam4.6619 Cited by (8) \| Cite \| Source
Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML (journal article) McCaw, Zachary R. \| Richardson, Paul G. \| Wei, Lee-Jen Journal of Clinical Oncology, volume 41, issue 27, pages 4446-4447 (2023). 10.1200/JCO.23.00465 Cite \| Source
MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis (journal article) Moreau, Philippe \| Perrot, Aurore \| Dimopoulos, Meletios-Athanasios \| Martin, Thomas \| Facon, Thierry \| Capra, Marcelo \| Beksac, Meral \| Armstrong, Nicole M \| Pharm, Franck Dubin \| Macé, Sandrine \| ... \| Richardson, Paul G. Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01424-6 Cite \| Source

Title	Investigators	Year	Cost	Agency
defibrotide for the treatment of severe hepatic veno-cc*	Richardson, Paul G	2007	$0	FOOD AND DRUG ADMINISTRATION
Defibrotide for the treatment of severe hepatic veno-cc*	Richardson, Paul G	2005	$0	FOOD AND DRUG ADMINISTRATION